Company Overview of LifeCell Corporation
LifeCell Corporation develops and markets tissue repair products for reconstructive, orthopedic, and urogynecologic biosurgery markets. The company’s products include Strattice Reconstructive Tissue Matrix and AlloDerm Regenerative Tissue Matrix for plastic, reconstructive, general surgical, burn, and periodontal procedures; Cymetra Regenerative Tissue Matrix, a particulate form of AlloDerm Tissue Matrix suitable for injection; and Repliform Regenerative Tissue Matrix for urogynecologic surgical procedures. It also offers GraftJacket for orthopedic surgical procedures; AlloCraft DBM for bone grafting procedures; and REVOLVE System that offers fat transfer processing in a range of aesthetic a...
One Millennium Way
Branchburg, NJ 08876-3876
Founded in 1986
Key Executives for LifeCell Corporation
Chief Executive Officer and President
Interim Chief Financial Officer
Chief Executive Officer of Kinetic Concepts Inc. and President of Kinetic Concepts Inc.
Senior Vice President of Development Regulatory Affairs & Quality
Principal Accounting Officer and Controller
Compensation as of Fiscal Year 2015.
LifeCell Corporation Key Developments
Lifecell Corporation Receives Jury Verdict from the United States District Court for the Eastern District of Virginia, Norfolk Division in a Patent Infringement Suit Filed by Lifenet Health
Nov 19 14
On November 18, 2014, LifeCell Corporation received a jury verdict from the United States District Court for the Eastern District of Virginia, Norfolk Division in a patent infringement suit filed by LifeNet Health against LifeCell in 2013. The jury found that LifeNet's U.S. Patent 6,569,200 was not invalid and was infringed by certain accused LifeCell regenerative tissue matrix products, and further awarded LifeNet a lump sum damages amount of $34.7 million. The company expects that LifeNet will seek pre-judgment interest on the damages amount. Any damages award that is maintained after appeal would be additionally subject to post-judgment interest. At this time the company is unable to estimate the range of damages related to pre- and post-judgment interest, or any further amounts LifeNet may seek in post-trial motions through costs, attorneys fees or otherwise. It is important to note that there will be no change in the supply or availability of LifeCell products as a result of this verdict, and LifeNet has not sought an injunction in the case.
KCI, Lifecell Corporation and Systagenix Wound Management, Limited Appoint Brian T. Busenlehner as Interim Chief Financial Officer
Nov 4 14
Effective October 29, 2014, Brian T. Busenlehner was appointed to the position of interim Chief Financial Officer for the company's operating subsidiaries, KCI, LifeCell Corporation and Systagenix Wound Management, Limited ('together with the Company, the Acelity Companies'). Since 2007, Mr. Busenlehner has served as Vice President, Corporate Controller of KCI and now the Acelity Companies.
Philip M. Croxford to Leave as President, Regenerative Medicine of LifeCell Corporation
Sep 30 14
LifeCell Corporation announced that effective September 24, 2014, Philip M. Croxford is leaving his position as President, Regenerative Medicine, to pursue other opportunities.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|